Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii-Reference-Cited by-同舟云学术

Prevalence and Clinical Consequences of Colistin Heteroresistance and Evolution into Full Resistance in Carbapenem-Resistant Acinetobacter baumannii

Published:2023-06-15 Issue:3 Volume:11 Page:
ISSN:2165-0497
Container-title:Microbiology Spectrum
language:en
Short-container-title:Microbiol Spectr

Author:

Kon Hadas¹,Hameir Amichay¹,Nutman Amir¹²,Temkin Elizabeth¹,Keren Paz Alona¹,Lellouche Jonathan¹³,Schwartz David¹,Weiss David S.⁴,Kaye Keith S.⁵,Daikos George L.⁶⁷,Skiada Anna⁶⁷,Durante-Mangoni Emanuele⁸⁹^ORCID,Dishon Benattar Yael¹⁰¹¹,Yahav Dafna²¹²^ORCID,Daitch Vered²¹³,Bernardo Mariano¹⁴,Iossa Domenico⁸,Friberg Lena E.¹⁵,Theuretzbacher Ursula¹⁶,Leibovici Leonard²¹³,Dickstein Yaakov¹⁰,Pollak Dina¹⁷,Mendelsohn Sigal¹⁷,Paul Mical¹⁰,Carmeli Yehuda¹²,Paul Mical,Dishon Benattar Yael,Dickstein Yaakov,Bitterman Roni,Zayyad Hiba,Koppel Fidi,Zak-Doron Yael,Altunin Sergey,Andria Nizar,Neuberger Ami,Stern Anat,Petersiel Neta,Raines Marina,Karban Amir,Leibovici Leonard,Yahav Dafna,Eliakim-Raz Noa,Zusman Oren,Elbaz Michal,Atamna Heyam,Daitch Vered,Babich Tanya,Carmeli Yehuda,Nutman Amir,Adler Amos,Levi Inbar,Daikos George L.,Skiada Anna,Pavleas Ioannis,Antoniadou Anastasia,Kotsaki Antigoni,Durante-Mangoni Emanuele,Andini Roberto,Iossa Domenico,Bernardo Mariano,Cavezza Giusi,Bertolino Lorenzo,Giuffre Giuseppe,Giurazza Roberto,Ruocco Giuseppe,Galdo Maria,Murino Patrizia,Cristinziano Adriano,Corcione Antonio,Zampino Rosa,Mouton Johan,Friberg Lena,Theuretzbacher Ursula

Affiliation:

1. National Institute for Antibiotic Resistance and Infection Control, Israel Ministry of Health, Tel Aviv, Israel

2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

3. Adelson School of Medicine, Ariel University, Israel

4. Emory Antibiotic Resistance Center, Emory University School of Medicine, Atlanta, Georgia, USA

5. Robert Wood Johnson Medical School, Rutgers University, New Brunswick, New Jersey, USA

6. First Department of Medicine, Laikon General Hospital, Athens, Greece

7. National and Kapodistrian University of Athens, Athens, Greece

8. Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy

9. AORN dei Colli-Monaldi Hospital, Naples, Italy

10. Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel

11. Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel

12. Infectious Diseases Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel

13. Department of Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel

14. Microbiology and Virology Unit, AORN Ospedali dei Colli-Monaldi Hospital, Naples, Italy

15. Department of Pharmacy, Uppsala University, Uppsala, Sweden

16. Center for Anti-Infective Agents, Vienna, Austria

17. Microbiology Laboratory, Rambam Health Care Campus, Haifa, Israel

Abstract

To our knowledge, this is the first large-scale study to report on HR in Gram-negative bacteria. We described the prevalence of colistin HR in a large sample of carbapenem-resistant A. baumannii isolates, the evolution of many colistin HR isolates to a resistant phenotype following colistin exposure and withdrawal, and the clinical consequences of colistin HR.

Funder

EU AIDA grant

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Cell Biology,Microbiology (medical),Genetics,General Immunology and Microbiology,Ecology,Physiology

Link

https://journals.asm.org/doi/pdf/10.1128/spectrum.05093-22

Reference34 articles.

1. World Health Organization. 2017. Global priority list of antibiotic-resistant bacteria to guide research discovery and development of new antibiotics. https://revive.gardp.org/wp-content/uploads/2023/01/WHO-global-PPL.pdf.

2. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

3. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

4. Antimicrobial Heteroresistance: an Emerging Field in Need of Clarity

5. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ineffectiveness of colistin monotherapy in treating carbapenem-resistant Acinetobacter baumannii Pneumonia: A retrospective single-center cohort study;Journal of Infection and Public Health;2024-05

2. Colistin heteroresistance in Citrobacter freundii clinical isolates from Republic of Korea;Diagnostic Microbiology and Infectious Disease;2024-04

3. Assessment of Colistin Heteroresistance among Multidrug-Resistant Klebsiella pneumoniae Isolated from Intensive Care Patients in Europe;Antibiotics;2024-03-20

4. Heteroresistance to piperacillin/tazobactam in Klebsiella pneumoniae is mediated by increased copy number of multiple β-lactamase genes;JAC-Antimicrobial Resistance;2024-03-05

5. Rates of resistance and heteroresistance to newer β-lactam/β-lactamase inhibitors for carbapenem-resistant Enterobacterales;JAC-Antimicrobial Resistance;2024-03-05